Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 7/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL31702788 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665748 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29777523 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL291157 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290572 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL23683025 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL17348307 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL663219 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29387962 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290347 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427188-B1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | PIRAMAL ENTPR LTD (IN) | 2016-08-10 | — | — | EP | claimed |
| EP-2748331-B1 | SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-03-02 | — | — | EP | claimed |
| US-8895605-B2 | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer | Piramal Enterprises Limited (IN) | 2014-11-25 | — | — | US | claimed |
| WO-2014140695-A1 | SOLID ORAL FORMULATION OF A PYRROLIDINE SUBSTITUTED FLAVONE COMPOUND | Piramal Enterprises Limited (IN) | 2014-09-18 | — | — | WO | claimed |
| US-8822526-B2 | Synergistic pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2014-09-02 | — | — | US | claimed |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | Piramal Enterprises Limited (IN) | 2013-02-21 | — | — | US | claimed |
| US-8304449-B2 | Inhibitors of cyclin dependent kinases and their use | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-11-06 | — | — | US | claimed |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2012-02-23 | — | — | US | claimed |
| EP-2154971-B1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-12-28 | — | — | EP | claimed |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-06-09 | — | — | US | claimed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | claimed |
| EP-2154971-A2 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Life Sciences Limited (IN) | 2010-02-24 | — | — | EP | claimed |
| WO-2008139271-A2 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-11-20 | — | — | WO | claimed |
| EP-1556375-B1 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LTD (IN) | 2008-06-25 | — | — | EP | claimed |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2008-05-08 | — | — | US | claimed |
| US-7271193-B2 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA, LTD. (IN) | 2007-09-18 | — | — | US | claimed |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-18 | — | — | US | claimed |
| EP-1556375-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | Nicholas Piramal India Limited (IN) | 2005-07-27 | — | — | EP | claimed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | claimed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | CDK4 5/4885CDK1 3/4885CDK9 2/4885 |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | CDK4 8/4885CDK1 3/4885CDK9 35/4885 |
| US-20120046334-A1 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER | CCNI, CCNK, CDK3 | CDK4 21/4885CDK1 13/4885CDK9 7/4885 |
| US-20080108690-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | CDK4 11/4885CDK1 1/4885CDK9 43/4885 |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | CDK1, CCNK, CCNI | CDK4 11/4885CDK1 1/4885CDK9 43/4885 |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | CDK4 7/4885CDK1 1/4885CDK9 38/4885 |
| US-20070015802-A1 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | CCNI, CDK1, CCNA1 | CDK4 7/4885CDK1 2/4885CDK9 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.